Just took another look at Inspire Medical's situation and honestly there's something worth paying attention to here. The company's been through a rough patch—down 25.6% over six months while the broader market's been climbing—but that actually might be creating an interesting entry point.

What caught my eye is how aggressively they're pushing their next-gen Inspire V neurostimulator. They literally just launched it in 2025 and already over 90% of their implant centers have adopted it. That's not normal adoption speed for medical devices. The new version integrates the respiratory sensor directly into the device, which simplifies the whole procedure. From a user experience standpoint, that's huge.

The clinical expansion story is solid too. They've treated more than 125,000 patients globally now, and the FDA's been opening up the addressable market—raised the apnea-hypopnea index limit to 100, bumped up the BMI threshold to 40, even cleared pediatric use for Down syndrome patients. That's regulatory tailwinds, not headwinds.

Now here's where it gets interesting. Inspire Medical beat earnings estimates in four straight quarters with an average 185.1% surprise. Most recent Q4 results? Better than expected across the board. They've got $308 million in cash, zero debt, and they're actually profitable now after years of losses. That's a meaningful inflection point.

Obviously there are risks. It's still basically a single-product company, so they're entirely dependent on Inspire system adoption. If adoption slows, there's not much of a fallback. Reimbursement challenges could pop up, patient reluctance to implants is always a factor, and the competitive landscape could shift.

But the estimate revision trend for 2026 is moving in the right direction—consensus earnings estimate moved up 21 cents to $1.93 per share in the last month. That's not huge but it's directionally positive.

Looks like INSP is in a solid position for the next few quarters while they navigate this product transition. The combination of regulatory expansion, strong adoption of the new device, and improving profitability makes it worth holding if you've got exposure. Not a screaming buy from here, but definitely one to keep on the radar in the medtech space.